EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Egalet Corporation to Contact the Firm
Accesswire 13-Jan-2017 10:47 AM
NEW YORK, NY / ACCESSWIRE / January 13, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Egalet Corporation ("Egalet" or the "Company") (NASDAQ: EGLT).
The investigation focuses on whether the Company and its executives violated federal securities laws.
Specifically, on January 9, 2017, Egalet issued a press release announcing the approval of its product Arymo ER. Later that day, the Federal Drug Administration issued a statement regarding Arymo ER's approval, indicating that another product, MorphaBond, "has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties." On this news, Egalet's share price was negatively affected.
Request more information now by clicking here: www.faruqilaw.com/EGLT. There is no cost or obligation to you.
If you invested in Egalet stock, bonds, or options and would like to discuss your legal rights, visit www.faruqilaw.com/EGLT. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330, or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Egalet's conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. email@example.com Telephone: (877) 247-4292 or (212) 983-9330
SOURCE: Faruqi & Faruqi, LLP